International Journal of STD & AIDS > Volume 18, Number 12 > Pp. 851-855

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Townsend, M. L Articles by Johnson, M. D Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia

Mary L Townsend, Stephanie B Hollowell, Jasmin Bhalodia, Kenneth H Wilson, Keith S Kaye and Melissa D Johnson

Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek, NC, USA; Department of Pharmacy, Durham Veterans Affairs Medical Center, Durham, NC, USA; Department of Pharmacy, CJW Medical Center, Richmond, VA, USA; Virginia Commonwealth School of Pharmacy, Richmond, VA, USA; Merck & Company, Rahway, NJ, USA; Division of Infectious Diseases & International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA; Division of Infectious Diseases, Durham Veterans Affairs Medical Center, Durham, NC, USA; Division of Infectious Diseases & International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA; Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek, NC, USA; Division of Infectious Diseases & International Health, Department of Medicine, Duke University Medical Center, Durham, NC, USA

This retrospective cohort study conducted at the Durham Veterans Affairs Medical Center evaluated the effectiveness and safety of lipid-lowering therapy (LLT) in a HIV-infected population as compared with a general population with hyperlipidaemia. Fifty-three HIV-infected subjects who developed dyslipidaemia and 53 age-matched non-HIV-infected subjects receiving LLT were selected. Efficacy of LLT was assessed after three and six months. Non-HIV-infected subjects were more likely to achieve total cholesterol (TC) goals at three and six months (P = 0.045, P = 0.005) and triglyceride (TG) goals at six months (P = 0.017). Less than 45% of HIV-infected subjects met National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) goals at three or six months. While non-HIV-infected subjects were more likely to achieve TC and TG goals than HIV-infected subjects, overall achievement of NCEP III goals was poor. This result was likely due to treatment with inappropriately low doses of statins.

Key Words: HYPERLIPIDAEMIA • HIV INFECTION • STATIN

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?